Cumberland Pharmaceuticals (CPIX)
Develops ifetroban for rare-disease complications while retaining a life-sciences venture interest.
$6.53
At close−0.03 (−0.46%)
Something off on this page? Send us feedback.
Next report
Nov 3, 2026
in 61 days
EPS estimate
−$0.13
Revenue estimate
$8.5M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.02$0.16$0.02−$0.06−$0.01−$0.13−$0.20Pending
Estimate————−$0.13−$0.13−$0.13−$0.13
Surprise————+92.3%0.0%−53.8%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$10.4M$11.7M$10.8M$8.3M$13.7M$9.1M$166.5KPending
Estimate————$8.5M$8.5M$8.5M$8.5M
Surprise————+60.9%+7.4%−98.0%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.13 | — | — |
| Aug 2026 | −$0.13 | −$0.20 | −53.8% |
| May 2026 | −$0.13 | −$0.13 | 0.0% |
| Mar 2026 | −$0.13 | −$0.01 | +92.3% |
| Nov 2025 | — | −$0.06 | — |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | −$0.13 | — | — | $8.5M | — | — | — |
| Aug 4, 2026 | −$0.13 | −$0.20 | −53.8% | $8.5M | $166.5K | −98.0% | −2.8% |
| May 5, 2026 | −$0.13 | −$0.13 | 0.0% | $8.5M | $9.1M | +7.4% | −4.0% |
| Mar 3, 2026 | −$0.13 | −$0.01 | +92.3% | $8.5M | $13.7M | +60.9% | −19.9% |
| Nov 4, 2025 | — | −$0.06 | — | — | $8.3M | — | −12.4% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Aug 5, 2025 | |||||||
| May 6, 2025 | |||||||
| Mar 4, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 6, 2024 | |||||||
| May 7, 2024 | |||||||
| Mar 5, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Aug 8, 2023 | |||||||
| May 9, 2023 | |||||||
| Mar 7, 2023 | |||||||
| Nov 8, 2022 | |||||||
| Aug 9, 2022 | |||||||
| May 10, 2022 | |||||||
| Mar 8, 2022 | |||||||
| Nov 9, 2021 | |||||||
| Aug 10, 2021 | |||||||
| May 11, 2021 | |||||||
| Mar 9, 2021 | |||||||
| Nov 10, 2020 | |||||||
| Aug 11, 2020 | |||||||
| May 20, 2020 | |||||||
| Mar 18, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 14, 2019 | |||||||
| May 14, 2019 | |||||||
| Feb 26, 2019 | |||||||
| Nov 13, 2018 | |||||||
| Aug 14, 2018 | |||||||
| May 8, 2018 | |||||||
| Mar 6, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 8, 2017 | |||||||
| May 15, 2017 | |||||||
| Mar 7, 2017 | |||||||
| Nov 1, 2016 | |||||||
| Aug 2, 2016 | |||||||
| May 10, 2016 | |||||||
| Mar 3, 2016 | |||||||
| Nov 3, 2015 | |||||||
| Aug 4, 2015 | |||||||